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A Modulator of Cardiac Contractility
3038-Symp
Modulating Contraction by Binding of MyBP-C to Actin
Roger Craig, Ph.D.
Cell Biology, UMass Medical School, Worcester, MA, USA.
Myosin-binding protein C (MyBP-C) is a ~130 kDa protein of the thick fila-
ments of vertebrate skeletal and cardiac muscle. It consists of a linear array
of ten or eleven globular, 10-kDa domains from the immunoglobulin (Ig)
and fibronectin type III families, and an additional, MyBP-C-specific motif.
The cardiac isoform, cMyBP-C, plays a key role in modulating cardiac func-
tion, and mutations in MyBP-C cause heart disease. Despite its discovery 40
years ago, the mechanism of MyBP-C function remains poorly understood.
In vitro studies suggest that it could modulate contraction by binding to thin fil-
aments, but there has been no evidence for this in situ. We used electron tomog-
raphy of exceptionally well-preserved skeletal muscle to study the 3D
organization of MyBP-C in the intact sarcomere. The tomogram shows that
MyBP-C projects perpendicular to the thick filament surface and reaches neigh-
boring thin filaments. This thick-thin filament bridge suggests a possible phys-
ical basis for modulating filament sliding and thus contraction. In vitro, binding
to actin has been shown to occur via MyBP-C’s N-terminal end. To understand
the structural basis of this binding, we used negative stain electron microscopy
and 3D reconstruction to study F-actin decorated with bacterially expressed
N-terminal cMyBP-C fragments. Clear decoration was obtained under a variety
of salt conditions. 3D reconstructions showed MyBP-C density starting over
subdomain 1 of actin and extending tangentially towards actin’s pointed end.
Molecular fitting with an atomic structure of a MyBP-C Ig domain suggested
that most of the N-terminal domains may be well ordered on actin. The location
of binding was such that it appeared to overlap the relaxed (low Ca2þ) position
of tropomyosin but not the activated position. This suggests that MyBP-C
might help determine the state of thin filament activity by modulating tropomy-
osin position on actin.
3039-Symp
Dynamic Regulation of Contraction by Cardiac Myosin Binding Protein-C
Samantha Harris.
Neurobiology, Physiology & Behavior, University of California, Davis,
Davis, CA, USA.
Cardiac myosin binding protein-C (cMyBP-C) is a thick filament associated
protein that performs both regulatory and structural roles within cardiac sarco-
meres. It is a member of the immunoglobulin (Ig) superfamily of proteins con-
sisting of 8 Ig- and 3 fibronectin (FNIII)-like subdomains along with a unique
regulatory sequence referred to as the M-domain whose structure is unknown.
Here we used atomic force microscopy (AFM) to probe the structure and me-
chanical properties of the different subdomains of native and recombinantly ex-
pressed cMyBP-C molecules. Results demonstrate that cMyBP-C exhibits
complex mechanical behavior under load and contains multiple domains
with distinct mechanical properties. The Ig and FNIII-like domains unfold
over a range of relatively low forces (50-190 pN), whereas the M-domain is
readily extensible at forces <50 pN and is likely to be an intrinsically disor-
dered segment of cMyBP-C. Additional extensible segments of cMyBP-C
are likely to include linkers between the Ig domains such as the proline-
alanine rich sequence between domains C0 and C1. Taken together these re-
sults suggest that cMyBP-C is compliant and readily extensible, potentially
conferring structural and functional plasticity to cMyBP-C during the course
of a single heart beat. Supported by NIH HL080367.
3040-Symp
Cardiac Myosin Binding Protein-C Phosphorylation, Contractile Function
and Cardioprotection
Sakthivel Sadayappan, Ph.D.
Department of Cell and Molecular Physiology, Stritch School of Medicine,
Loyola University Chicago, Maywood, IL, USA.
Cardiac myosin binding protein-C (cMyBP-C) is a sarcomeric thick filament
assembly protein with regulatory functions in the heart. The cMyBP-C protein
differs from the skeletal isoform in that it has a small insertion near the car-
boxyl terminus that contains 3 phosphorylatable serines, Ser-273, 282 and
302. While the precise functional correlates of cMyBP-C phosphorylation re-
main obscure, we do know that cMyBP-C is targeted by multiple kinases, such
as PKA, PKC, RSK, PKD, CaMKII and PKG, suggesting that it plays a vital
role in cardiac signaling. We previously reported that cMyBP-C phosphoryla-
tion is essential for normal heart function and that Ser-282 phosphorylation iscritical for the subsequent phosphorylation of Ser-302 and normal cardiac
function. However, the role of Ser-282 cMyBP-C phosphorylation in cardiac
function, particularly as it affects contractile properties and sarcomere organi-
zation, is unclear. Therefore, to better understand the mechanisms and signif-
icance of cMyBP-C phosphorylation, we established several transgenic mouse
models to determine the necessity and sufficiency of Ser-282 phosphorylation
for normal cardiac function. Our findings suggested that cMyBP-C phosphor-
ylation at Ser-282 is essential for normal cardiac function and that dephosphor-
ylation at this site accelerates cMyBP-C degradation and cleavage of a 40 kDa
fragment. During MI, we showed that cMyBP-C is extensively fragmented
when dephosphorylated and that such fragmentation correlates well with con-
tractile dysfunction and heart failure. Meanwhile, we also established that the
release of cMyBP-C in the blood post-MI could be a potential diagnostic bio-
marker for MI. Overall, these studies show that Ser-282 phosphorylation is
a critical determinant of Ser-302 phosphorylation and that cMyBP-C dephos-
phorylation accelerates its degradation and release into the circulation. In con-
clusion, we provide strong evidence that cMyBP-C phosphorylation directly
affects the heart’s contractile properties, sarcomere organization and
cardioprotection.
3041-Symp
Cardiac Myosin Binding Protein C Phosphorylation in Human Cardiac
Disease
Jolanda van der Velden1, Diederik W.D. Kuster2.
1Physiology, Institute for Cardiovascular Research VU University Medical
Center, Amsterdam, Netherlands, 2Institute for Cardiovascular Research VU
University Medical Center, Amsterdam, Netherlands.
During recent years it has become increasingly evident that cardiac myosin
binding protein C (cMyBP-C) exerts an important role in regulation of
sarcomere function with consequences for in vivo cardiac performance.
The functional role of cMyBP-C is tightly regulated by kinase-mediated
phosphorylation. The most important kinase which phosphorylates
cMyBP-C in vivo is protein kinase A (PKA), which is activated upon stimu-
lation of the b-adrenergic receptors during exercise. In end-stage failing hu-
man myocardium, reduced phosphorylation of cMyBP-C has been reported
using 1-dimensional and 2-dimensional gel electrophoresis. This reduced
phosphorylation has been attributed to down-regulation and desensitization
of the b-adrenergic receptor pathway in end-stage human heart failure.
Low levels of cMyBP-C phosphorylation were also found in patients with
familial hypertrophic cardiomyopathy (FHC), which is frequently caused by
mutations in genes encoding sarcomeric proteins, with one exception: in
FHC patients with mutations in the gene which encodes cMyBP-C
(MYBPC3), phosphorylation of cMyBP-C was unaltered compared to non-
failing donor hearts. cMyBP-C can be phosphorylated in vivo on at least three
serine sites (Ser273, Ser282 and Ser 302), all of which are located in the car-
diac isoform specific M region. At least one other site should exist in humans.
With tandem mass spectrometry we recently identified a fourth phosphoryla-
tion site on Ser133, which is present in the Pro-Ala rich region that links the
C0 and C1 domains. Preliminary data indicate that Ser133 is not phosphory-
lated by PKA. Analysis of phosphorylation on Ser133 in failing and donor
samples revealed lower levels of Ser133 phosphorylation in several forms
of cardiac disease compared to non-failing myocardium. Overall, our studies
indicate that diverse cMyBP-C phosphorylation patterns exist in human car-
diomyopathies, which may in part underlie sarcomere dysfunction observed
in human heart failure.Symposium: Materials Science Meets Biology
3042-Symp
Engineering Cooperative Nanosytems
Sangeeta Bhatia.
Massachusetts Institute of Technology, Cambridge, MA, USA.
Our laboratory is interested in engineering tools and systems using nanoparticle
scaffolds to transform the diagnosis and treatment of cancer. We aim to inte-
grate nanomaterials with enhanced nanoscale properties and bioresponsive
functionalities with our knowledge of the tumor microenvironment to explore
this paradigm. Towards this end, we have developed and investigated nanopar-
ticle conjugates based on three nanoparticle cores that harness features of the
nanoscale: semiconductor quantum dots that exhibit size-based optical proper-
ties, dextran-coated iron oxide particles whose assembly alters the spin-spin re-
laxation time of hydrogen protons on magnetic resonance imaging, and
polymer-coated gold nanorods that interact resonantly with near-infrared light.
Our studies have shown how these nanoparticles specifically designed to
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geting, triggered self-assembly, remote actuation with radiofrequency fields,
sensing of kinase activity, and delivery of short interfering RNAs. In collabo-
ration with Erkki Ruoslahti (Burnham Institute), we have explored how deco-
rating the surface with peptides obtained from in vivo phage display can alter
the properties of these nanoparticles and control their trafficking. To increase
the accumulation of the nanoparticles at the tumor site we are exploring
in vivo self-assembly of these particles. Our approach is inspired by platelets_
natural microparticles that normally circulate in a latent form but can home to
sites of injury and transform to an activated state, whereby they adhere and re-
cruit more platelets. This results in assemblies of magnetic nanoparticles that
may then acquire emergent properties, allowing either their enhanced visuali-
zation or remote actuation of drug delivery. More recently, we have also emu-
lated biological systems where biological components remotely communicate
via biological intermediates. The resultant nanoparticle formulations then act
as a ‘‘system’’ to produce emergent behaviors for enhancing diagnosis and
therapy.
3043-Symp
Co-Opting Moore’s Law: Vaccines and Medicines made from a Wafer
Joseph M. DeSimone1,2.
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,
2North Carolina State University, Raleigh, NC, USA.
In 1965, Gordon Moore, co-founder of Intel, described the trend that the num-
ber of components in integrated circuits had doubled every year since 1958.
This trend has continued to today, enabled by advances in photolithography
which has taken the minimum feature size of transistors down from about
10 microns in 1970 to 0.045 microns (45 nm) today. In biological terms,
this corresponds to going from the size of a red blood cell to the size of a sin-
gle virus particle! As such, this top-down nano-fabrication technology from
the semiconductor industry is, for the first time, in the size range to be rele-
vant for the design of medicines, vaccines and interfacially active Janus par-
ticles. This lecture will describe the design, synthesis and efficacy of organic
nano- and micro-particles using a top-down nano-fabrication technique we de-
veloped called PRINT (Particle Replication in Non-wetting Templates).
PRINT is a continuous, roll-to-roll, high resolution molding technique that al-
lows the fabrication of precisely defined micro- and nano-particles in a contin-
uous manner with control over chemical composition, size, shape,
deformability and surface chemistry. With these ‘nanotools’, we are establish-
ing definitive biodistribution maps to elucidate the interdependent roles that
size, shape, deformability and surface chemistry play on particle distribution
as a function of different dosage forms (IV, IP, inhaled, subcutaneous, intra-
muscular, etc). This information is setting the stage for the design of highly
effective chemo-therapeutics, chemo-preventions and cancer vaccines which
will be described.
3044-Symp
Studies in the Three-Dimensional World of a Cancer Community of Cells
Robert Austin, Liyu Liu, Bo Sun, Howard Stone.
Princeton University, Princeton, NJ, USA.
Cancer is a dynamic condition in a complex community of cells which move
and communicate in 3-D space and complex topologies. We will present results
using 3-Dmicrofabrication and materials science which maps out how the com-
munity moves and invades.
3045-Symp
Engineering of Polymeric Nanoparticles from Medical Applications
Omid C. Farokhzad.
Brigham and Womens Hospital and Harvard Medical School, Boston,
MA, USA.
A variety of organic and inorganic materials have been utilized to generate
nanoparticles for drug delivery applications, including polymeric nanopar-
ticles, dendrimers, nanoshells, liposomes, nucleic acid based nanoparticles,
magnetic nanoparticles, and virus nanoparticles. The two most commonly
used systems are polymeric nanoparticles and liposomes. Controlled release
polymer technology has impacted virtually every branch of medicine, includ-
ing ophthalmology, pulmonary, pain medicine, endocrinology, cardiology, or-
thopedics, immunology, neurology and dentistry, with several of these systems
in clinical practice today such as Atridox, Lupron Depot, Gliadel, Zoladex,
Trelstart Depot, Risperidol Consta and Sandostatin LAR. The annual world-
wide market of controlled release polymer systems which extends beyond
drug delivery is now estimated at $100 billion and these systems are used
by over 100 million people each year. Polymeric nanoparticles can deliver
drugs in the optimum dosage over time, thus increasing the efficacy of the
drug, maximizing patient compliance and enhancing the ability to use highly
toxic, poorly soluble, or relatively unstable drugs. These systems can also beused to co-deliver two or more drugs for combination therapy. The surface en-
gineering of these nanoparticles may yield them ‘‘stealth’’ to prolong their res-
idence in blood and the functionalization of these particles with targeting
ligands can differentially target their delivery or uptake by a subset of cells,
further increasing their specificity and efficacy. More recently combinatorial
approaches have been developed to precisely engineer nanoparticles and
screen multiple nanoparticle characteristics simultaneously with the goal of
identifying formulations with the desired physical and biochemical properties
for each specific application. The goal of this talk is to review our efforts in the
design and optimization of polymeric nanoparticles for medical applications,
which formed the foundation for the clinical translation of the first-in-
human targeted and controlled-release nanoparticles (BIND-014) for cancer
therapy.Platform: Emerging Single Molecule Techniques
3046-Plat
Fast Three-Dimensional Imaging and Tracking of Single Molecules in the
Nucleus of Live Cells using a Multifocal Microscope
Jiji Chen1, Bassam Hajj1, Sara Abrahamsson1, David Grunwald2,
Mats Gustaffson1, Maxime Dahan1,3.
1HHMI, Janelia Farm Research Campus, Transcription Imaging Consortium,
Ashburn, VA, USA, 2Delft University, Delft, Netherlands, 3Ecole normale
supe´rieure, Paris, France.
Deciphering the dynamic nature of biological processes requires developing
tools for monitoring the behavior of single molecules (SMs) in live cells. How-
ever, a key challenge lies in the difficulty of imaging and tracking SM in
three dimensions, notably for intracellular proteins that tend to diffuse rapidly
(> 0.5 um2/s). Methods currently employed for sub-diffraction 3D localization
of individual fluorophores are limited to an axial depth of ~1 um or less. Here
we present a novel multifocal microscope that permits the rapid (up to
30 frames/s) acquisition of 3D stacks. The microscope is based on the incorpo-
ration in the emission pathway of a multi-focus diffraction grating combined
with a chromatic-correction grating in order to simultaneously detect 9 differ-
ent axial planes on a single detector camera. Thereby, the system allows for
aberration-free detection of individual molecules over an axial distance of up
to 5 um. The microscope characteristics are particularly appropriate for probing
the dynamics of individual molecules in the nucleus of cultured cells. This ca-
pability is demonstrated by recording the 3Dmotion of individual inert markers
(beads or quantum dots), mRNAs, histone H2B proteins or transcription factors
in live mammalian cells. Overall, our multifocal microscope, with its ease of
use and performances, holds great promise for fast and sensitive 3D imaging
in many cellular contexts.
3047-Plat
Fluorescence Triple Correlation Spectroscopy Resolves Ten Intermediates
Along Different Parallel Ribosome Assembly Pathways
William K. Ridgeway, David P. Millar, James R. Williamson.
The Scripps Research Institute, La Jolla, CA, USA.
Efficient self-assembly of the bacterial 30S ribosomal subunit depends on the
interplay of a large number of sequential RNA folding and protein binding
events. In many cases the order of these events is not rigidly defined, giving
rise to an assembly landscape crossed by parallel assembly pathways. The bi-
ological and biophysical implications of parallel assembly are unclear, and
seem to contradict the current understanding of the ways large RNAs avoid ki-
netic traps. There has been very little direct characterization of the degree of
parallel assembly in ribosomes because current biophysical techniques have
difficulty resolving intermediates, especially with a large macromolecule
(>500kDa) that requires high concentrations (100-1000nM) to assemble.
To quantitate 30S intermediates, Fluorescence Correlation Spectroscopy (FCS)
was extended to create Fluorescence Triple Correlation Spectroscopy (F3CS).
By correlating three signals, F3CS can study complex stoichiometric systems,
kinetic processes and irreversible reactions. Theory, numerical correlation
strategies, and experimental practices were established and a two-photon exci-
tation, three-color detection microscope was built to perform the first F3CS
measurements. The technique is implemented as a suite of software, Triple Cor-
relation Toolbox, to enable triple correlation experiments with existing
microscopes.
F3CS simultaneously identified intermediates both on and off the ribosome as-
sembly pathways that were predicted by classic assembly maps. A weak ener-
getic bias favors one assembly pathway over the others, but the bias energy is
not strong enough to prevent the formation of intermediates off of the favored
pathway. The interaction energies of ribosomal proteins S7, S9 and S19 are ini-
tially weak, which in principle reduces the potential for kinetic traps. F3CS has
